Brad Canino Analyst PerformanceBiotechnology Equity Research Analyst at GuggenheimBrad Canino is a stock analyst at Guggenheim in the medical sector, covering 18 publicly traded companies. Over the past year, Brad Canino has issued 44 stock ratings, including strong buy, buy, and hold recommendations. While full access to Brad Canino's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Brad Canino's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings44 Last 0 YearsBuy Recommendations93.18% 41 Buy RatingsCompanies Covered18 Unique Companies Ratings Distribution44RatingsDistribution of strong buy, buy, hold, and sell ratings by Brad Canino.RatingPercentageCount Strong Buy2.3%1 ratings Buy90.9%40 ratings Hold6.8%3 ratings Sell0.0%0 ratingsOut of 44 total stock ratings issued by Brad Canino at Guggenheim, the majority (90.9%) have been Buy recommendations, followed by 6.8% Hold and 2.3% Strong Buy.Best & Worst CallsThis analyst does not have any ratings with enough history to determine best and worst calls.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ18 companiesBrad Canino, an analyst at Guggenheim, currently covers 18 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical18 companies100.0%Brad Canino of Guggenheim specializes in stock coverage within the Medical sector.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE14 companies77.8%MED - DRUGS4 companies22.2% Brad Canino's Ratings History at Guggenheim Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsNUVLNuvalent6/10/2026Downgrade$123.25$124.00Neutral$0.0000.00% ROICELCCelcuity6/3/2026Reiterated Rating$91.42Buy$0.0000.00% ROIRLAYRelay Therapeutics5/26/2026Boost Price Target$13.53$26.00Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals5/13/2026Lower Price Target$13.30$35.00Buy$0.0000.00% ROIBCAXBicara Therapeutics5/11/2026Initiated Coverage$22.58$42.00Buy$0.0000.00% ROIBCAXBicara Therapeutics5/10/2026Upgrade$22.92Strong-Buy$0.0000.00% ROIJANXJanux Therapeutics5/8/2026Lower Price Target$14.54$58.00Buy$0.0000.00% ROICELCCelcuity5/4/2026Boost Price Target$125.65$165.00Buy$0.0000.00% ROITYRATyra Biosciences4/14/2026Initiated Coverage$35.27$54.00Buy$0.0000.00% ROITYRATyra Biosciences4/14/2026Initiated Coverage$34.97$54.00Buy$0.0000.00% ROI Get the Latest News and Ratings for Your StocksEnter your email address below to receive the latest headlines and analysts' recommendations for your stocks with our free daily email newsletter. OLMAOlema Pharmaceuticals3/17/2026Lower Price Target$16.60$38.00Buy$0.0000.00% ROIRLAYRelay Therapeutics3/13/2026Boost Price Target$10.55$22.00Buy$0.0000.00% ROIJANXJanux Therapeutics2/27/2026Lower Price Target$13.80$68.00Buy$0.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock2/17/2026Reiterated Rating$29.12$40.00Buy$0.0000.00% ROICGEMCullinan Therapeutics2/2/2026Initiated Coverage$11.96$30.00Buy$0.0000.00% ROICGEMCullinan Therapeutics2/2/2026Initiated Coverage$13.21$30.00Buy$0.0000.00% ROICBIOCrescent Biopharma1/21/2026Initiated Coverage$13.98$35.00Buy$0.0000.00% ROICBIOCrescent Biopharma1/21/2026Initiated Coverage$13.72$35.00Buy$0.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock12/8/2025Boost Price Target$27.46$36.00Buy$0.0000.00% ROIBDTXBlack Diamond Therapeutics12/3/2025Downgrade$2.63Neutral$0.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock12/1/2025Initiated Coverage$17.35$32.00Buy$0.0000.00% ROIDMRADamora Therapeutics, Inc. Common Stock12/1/2025Initiated Coverage$17.77$32.00Buy$0.0000.00% ROINUVLNuvalent11/18/2025Boost Price Target$105.51$155.00Buy$0.0000.00% ROIKYMRKymera Therapeutics11/3/2025Initiated Coverage$61.84$90.00Buy$0.0000.00% ROIKYMRKymera Therapeutics11/3/2025Initiated Coverage$59.72$90.00Buy$0.0000.00% ROISMMTSummit Therapeutics10/22/2025Reiterated Rating$18.74$40.00Buy$0.0000.00% ROIOLMAOlema Pharmaceuticals10/8/2025Initiated Coverage$10.44$20.00Buy$0.0000.00% ROICGONCG Oncology10/7/2025Initiated Coverage$38.00$90.00Buy$0.0000.00% ROICGONCG Oncology10/7/2025Initiated Coverage$40.71$90.00Buy$0.0000.00% ROICELCCelcuity9/22/2025Initiated Coverage$51.88Buy$0.0000.00% ROIKURAKura Oncology9/4/2025Initiated Coverage$8.43Neutral$0.0000.00% ROIORICOric Pharmaceuticals9/4/2025Initiated Coverage$10.60$18.00Buy$0.0000.00% ROIRLAYRelay Therapeutics9/4/2025Initiated Coverage$4.02$15.00Buy$0.0000.00% ROINUVLNuvalent9/4/2025Initiated Coverage$78.82$122.00Buy$0.0000.00% ROISMMTSummit Therapeutics9/3/2025Initiated Coverage$23.52$40.00Buy$0.0000.00% ROIPYXSPyxis Oncology9/3/2025Initiated Coverage$1.47$5.00Buy$0.0000.00% ROIJANXJanux Therapeutics9/3/2025Initiated Coverage$23.04$72.00Buy$0.0000.00% ROICCCCC4 Therapeutics9/3/2025Initiated Coverage$2.56$8.00Buy$0.0000.00% ROIBDTXBlack Diamond Therapeutics9/3/2025Initiated Coverage$2.88$8.00Buy$0.0000.00% ROIBDTXBlack Diamond Therapeutics9/3/2025Initiated Coverage$2.94$8.00Buy$0.0000.00% ROI"You need transformers to run transformers" — Musk (Ad)Elon Musk recently laughed nervously and said, 'You need transformers to run transformers.' That wasn't a punchline - it's a constraint printed in the SPCX prospectus for a $2 trillion company. The world's largest supercomputer requires power equipment that takes 120 weeks to build. Musk built Colossus in 122 days. One small American company can close that gap faster than anyone else, and Wall Street still hasn't priced it in.See the ticker Dylan Jovine says bridges that gap todayJANXJanux Therapeutics9/3/2025Initiated Coverage$23.98$72.00Buy$0.0000.00% ROIPYXSPyxis Oncology9/3/2025Initiated Coverage$1.91$5.00Buy$0.0000.00% ROICCCCC4 Therapeutics9/3/2025Initiated Coverage$2.71$8.00Buy$0.0000.00% ROISMMTSummit Therapeutics9/3/2025Initiated Coverage$19.44$40.00Buy$0.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenMorgan StanleyHSBCUBS GroupCitigroupBarclaysWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTD CowenTruist FinancialPiper SandlerStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
